Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study - statnews.com
Eli Lilly's VERVE-102 base editor reduced PCSK9 by up to 88% and LDL-C by up to 62% in early study, with durable effects positioning it as a potential one-time treatment for hypercholesterolemia — directly competing with chronic PCSK9 inhibitors. Lilly is prepping a Phase 2 launch, creating a medium-term catalyst path that could validate a major new pipeline asset at a time when the stock has lagged peers.
What happened
Eli Lilly's VERVE-102 base editor reduced PCSK9 by up to 88% and LDL-C by up to 62% in early study, with durable effects positioning it as a potential one-time treatment for hypercholesterolemia — directly competing with chronic PCSK9 inhibitors.
The read · May 25
Long LLY / short AMGN as a pair: VERVE-102 success threatens Repatha's chronic franchise while Lilly gains durable-dosing optionality heading into Phase 2.
Wrong if
Phase 2 data disappoints on safety (off-target editing events), or AMGN diversifies narrative away from Repatha; insider selling in LLY (2 sellers, 0 buyers last 30 days) is a mild headwind suggesting insiders aren't leaning in here.
CoverageSource: Google News · Published here MON, MAY 25 · 8:50 AM ET · the only report in this recordHow this is decided →
The chart · LLYTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
The read, in fullWhy it matters
VERVE-102 cutting LDL-C 62% with a single dose directly threatens the recurring-prescription model of AMGN's Repatha and REGN's Praluent — a 'one-and-done' label disrupts the chronic PCSK9 inhibitor market these two depend on. LLY trades at consensus Buy (19B/11SB) with BofA freshly revising its target today, suggesting some institutional re-rating is already underway. AMGN derives meaningful revenue from Repatha and trades at a richer multiple than the pipeline threat currently prices in, making the long LLY / short AMGN pair more defensive than a naked LLY long.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written · closes shown from MAY 26 on
Next · what would move this
4-8 weeks into Phase 2 initiation. Follow to be told when one lands.
Since this story · named here, equal weight · 1D EOD+22.8%
MAY 26 · first close after publicationSEP 4
Price context does not establish that the story caused the move.
Receipts
Google News — the original8:50 AM
Research, not advice.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →
Reaction = the first close after the story against the close before it. Prior-session closes only; not a call.
The memory
This page is kept as it was written on May 25. Later coverage joins it only when the company and catalyst evidence match, and what the stock did is shown from licensed end-of-day closes — never re-graded, never backdated. The judgment is yours.